Primary CD8+ T cells isolated from the human blood and modified with chimeric antigen receptors (CAR) to express high affinity to tumor antigens have been large used in the clinical practice to treat patients with hematological malignancies (59, 60). The gene discussed is CD8A; the disease is hematologic disorder.